Replies to post #162524 on Biotech Values

[DewDiligence]

XOMA’s partner, Servier, starts PoC trial of Gevokicumab in polymyositis/dermatomyositis:

http://finance.yahoo.com/news/xomas-development-partner-servier-launches-130000127.html

"SERVIER believes gevokizumab has the potential to treat a wide range of indications beyond Behcet's uveitis, non-infectious uveitis, and cardiovascular diseases," stated John Varian, Chief Executive Officer of XOMA. "We are impressed with the breadth and depth of SERVIER's development plan. The first indication they are studying is polymyositis/dermatomyositis. Once SERVIER's POC program is fully underway, we anticipate gevokizumab will be undergoing safety and efficacy evaluations in over a dozen potential indications between SERVIER's and our efforts."

Servier’s Gevokicumab PoC trials are separate from the three PoC indications being pursued by XOMA itself: severe acne, erosive osteoarthritis of the hand (EOH), and non-anterior scleritis.

[DewDiligence]

Transcript of XOMA webcast at JMP today:

http://www.earningsimpact.com/Transcript/82084/XOMA/JMP-Securities-2013-Healthcare-Conference

Caution: There are a lot of typos and other errors in the transcript.

[DewDiligence]

XOMA ($5.16) 2-year intraday high today (eom).

[DewDiligence]

XOMA—Data readouts from EYEGUARD-A and -C delayed due to slow opening of ex-US sites. Possible BLA filing based on EYEGUARD-B only, according to CC in progress now.